Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESS… Read more
Market Cap & Net Worth: Neurocrine Biosciences Inc (NBIX)
Neurocrine Biosciences Inc (NASDAQ:NBIX) has a market capitalization of $13.12 Billion ($13.12 Billion) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #1393 globally and #1058 in its home market, demonstrating a 0.60% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Neurocrine Biosciences Inc's stock price $130.71 by its total outstanding shares 100363463 (100.36 Million).
Neurocrine Biosciences Inc Market Cap History: 2015 to 2026
Neurocrine Biosciences Inc's market capitalization history from 2015 to 2026. Data shows growth from $5.68 Billion to $13.12 Billion (9.88% CAGR).
Index Memberships
Neurocrine Biosciences Inc is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Biotechnology
BTK
|
$879.22 Billion | 1.47% | #15 of 30 |
|
Dow Jones Biotechnology
DJUSBT
|
$1.15 Trillion | 1.13% | #11 of 39 |
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.58% | #29 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.04% | #195 of 3165 |
|
S&P Midcap 400
MID
|
$3.04 Trillion | 0.36% | #50 of 401 |
|
NASDAQ Biotechnology
NBI
|
$1.54 Trillion | 0.84% | #18 of 263 |
Weight: Neurocrine Biosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Neurocrine Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Neurocrine Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.98x
Neurocrine Biosciences Inc's market cap is 4.98 times its annual revenue
1.02x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
29.74x
Neurocrine Biosciences Inc's market cap is 29.74 times its annual earnings
10.35x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.88 Billion | $15.00 Million | -$141.09 Million | 258.94x | N/A |
| 2017 | $7.79 Billion | $161.63 Million | -$142.54 Million | 48.18x | N/A |
| 2018 | $7.17 Billion | $451.24 Million | $21.11 Million | 15.88x | 339.49x |
| 2019 | $10.79 Billion | $788.10 Million | $37.00 Million | 13.69x | 291.57x |
| 2020 | $9.62 Billion | $1.05 Billion | $407.30 Million | 9.20x | 23.62x |
| 2021 | $8.55 Billion | $1.13 Billion | $89.60 Million | 7.54x | 95.40x |
| 2022 | $11.99 Billion | $1.49 Billion | $154.50 Million | 8.05x | 77.59x |
| 2023 | $13.22 Billion | $1.89 Billion | $249.70 Million | 7.01x | 52.96x |
| 2024 | $13.70 Billion | $2.36 Billion | $341.30 Million | 5.82x | 40.14x |
| 2025 | $14.23 Billion | $2.86 Billion | $478.60 Million | 4.98x | 29.74x |
Competitor Companies of NBIX by Market Capitalization
Companies near Neurocrine Biosciences Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Neurocrine Biosciences Inc by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Neurocrine Biosciences Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Neurocrine Biosciences Inc's market cap moved from $5.68 Billion to $ 13.12 Billion, with a yearly change of 9.88%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $13.12 Billion | -7.84% |
| 2025 | $14.23 Billion | +3.90% |
| 2024 | $13.70 Billion | +3.60% |
| 2023 | $13.22 Billion | +10.31% |
| 2022 | $11.99 Billion | +40.24% |
| 2021 | $8.55 Billion | -11.14% |
| 2020 | $9.62 Billion | -10.83% |
| 2019 | $10.79 Billion | +50.53% |
| 2018 | $7.17 Billion | -7.96% |
| 2017 | $7.79 Billion | +100.49% |
| 2016 | $3.88 Billion | -31.59% |
| 2015 | $5.68 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Neurocrine Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.12 Billion USD |
| MoneyControl | $13.12 Billion USD |
| MarketWatch | $13.12 Billion USD |
| marketcap.company | $13.12 Billion USD |
| Reuters | $13.12 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.